(Q37141921)

English

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

scientific article published on 24 February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients (English)

1 reference

Europe PubMed Central

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

brain metastasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Y H Park

1

1 reference

Europe PubMed Central

18 August 2017

M J Park

2

1 reference

Europe PubMed Central

18 August 2017

S H Ji

3

1 reference

Europe PubMed Central

18 August 2017

S Y Yi

4

1 reference

Europe PubMed Central

18 August 2017

D H Lim

5

1 reference

Europe PubMed Central

18 August 2017

D H Nam

6

1 reference

Europe PubMed Central

18 August 2017

J-I Lee

7

1 reference

Europe PubMed Central

18 August 2017

W Park

8

1 reference

Europe PubMed Central

18 August 2017

D H Choi

9

1 reference

Europe PubMed Central

18 August 2017

S J Huh

10

1 reference

Europe PubMed Central

18 August 2017

J S Ahn

11

1 reference

Europe PubMed Central

18 August 2017

W K Kang

12

1 reference

Europe PubMed Central

18 August 2017

K Park

13

1 reference

Europe PubMed Central

18 August 2017

Y-H Im

14

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

24 February 2009

1 reference

Europe PubMed Central

18 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

18 August 2017

100

1 reference

Europe PubMed Central

18 August 2017

6

1 reference

Europe PubMed Central

18 August 2017

894-900

1 reference

Europe PubMed Central

18 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604941

0 references

Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

6 September 2017

Brain metastases: the HER2 paradigm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

6 September 2017

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

6 September 2017

Rational surveillance programs for early stage breast cancer patients after primary treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

6 September 2017

CNS metastases in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

6 September 2017

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

6 September 2017

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

6 September 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

6 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

6 September 2017

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

14 September 2017

Determinants and prognoses of locoregional and distant progression in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

14 September 2017

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

27 June 2018

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

27 June 2018

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

27 June 2018

The natural history of breast cancer patients with brain metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

27 June 2018

Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Primary breast cancer phenotypes associated with propensity for central nervous system metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Trends in breast cancer by race and ethnicity: update 2006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Survival after brain metastases from breast cancer in the trastuzumab era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Central nervous system metastasis from breast carcinoma. Autopsy study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

3 September 2018

Cancer incidence and mortality in Europe, 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661774

4 December 2018

Breast cancer: metastatic patterns and their prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19240719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19240719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

1 reference

https://pubmed.ncbi.nlm.nih.gov/19240719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in CSF

1 reference

https://pubmed.ncbi.nlm.nih.gov/19240719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6604941

1 reference

Europe PubMed Central

18 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37141921&oldid=2167370336"